Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients

ClinicoEconomics and Outcomes Research

Volumn 9, Issue , 2017, Pages 451-458

  Aletaha, Daniel ^a   Snedecor, Sonya J ^b   Ektare, Varun ^b   Xue, Mei ^b   Bao, Yanjun ^c   Garg, Vishvas ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PHARMERIT INTERNATIONAL   (United States)

^c ABBVIE INC   (United States)

Author keywords

Biologics withdrawal; Dose reduction; Economic analysis; Flare

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL OUTCOME; COST BENEFIT ANALYSIS; DAS28; DISEASE ACTIVITY; DISEASE CONTROL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH ECONOMICS; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; REMISSION; RETREATMENT; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 85029520563     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S136327     Document Type: Article

References (31)

1. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol. 2008;18(5):460–464.
2. Tanaka Y, Hirata S, Fukuyo S, et al. Discontinuation of adalimumab without functional and structural progress after attaining remission in patients with rheumatoid arthritis. Arthritis Rheum. 2011;63:2468.
3. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16(5):585–591.
4. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322.
5. Lajas C, Abasolo L, Bellajdel B, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 2003;49(1):64–70.
6. Schoels M, Wong J, Scott DL, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):995–1003.
7. Kavanaugh A, Smolen JS. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials. Clin Exp Rheumatol. 2013;31(4 Suppl 78): S19–S21.
8. Ministry of Health and Welfare, National Health Insurance Administration, Secondary National Health Insurance Administration. Drug payment regulations. Available from: http://www.nhi.gov.tw/webdata/webdata.aspx?menu=18&menu_id=683&webdata_id=2919. Accessed June 15, 2017.
9. González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, et al; Spanish Rheumatology Society; Spanish Rheumatology Society. Spanish Rheumatology Society and Hospital Pharmacy Society consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015;54(7):1200–1209.
10. Yoshida K, Sung YK, Kavanaugh A, et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis. 2014;73(3):595–599.
11. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS- a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10(4):325–337.
12. Beresniak A, Ariza-Ariza R, Garcia-Llorente JF, Ramirez-Arellano A, Dupont D. Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain. Int J Inflam. 2011;2011:727634.
13. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet. 2014;383(9914):321–332.
14. Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R; ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2015;74(5):890–896.
15. Hirata S, Saito K, Kubo S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. 2013;15(5):R135.
16. Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74(2):389–395.
17. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918–929.
18. Emery P, Hammoudeh M, Fitzgerald O, et al. Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the PRIZE study. Ann Rheum Dis. 2013;72(Suppl 3):A399.
19. van Vollenhoven RF, Franck-Larsson K, Leirisalo-Repo M, et al. In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept at 50 mg or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-arm, double-blind study. Ann Rheum Dis. 2013; 72(Suppl 3):A434–A435.
20. Yamanaka H, Seto Y, Nagaoka S, et al. Discontinuation of etanercept in early rheumatoid arthritis patients who have achieved sustained remission: results of the randomized controlled trial in period 2 of the ENCOURAGE study. Ann Rheum Dis. 2014;73(Suppl 2):239.
21. Greenberg JD, Shan Y, Reed GW, Bitman B, Collier D. Comparison of switching to reduced dose vs continuation of standard dose etanercept for rheumatoid arthritis patients in the CORRONA registry. Ann Rheum Dis. 2014;73(Suppl 2):241.
22. Campbell RC, Sanders E, Leone F, Gilgeours E, Sibley M, Kiely PD. The cost savings associated with a departmental etanercept dose reduction pathway for patients with rheumatic diseases and maintained low disease activity. Arthritis Rheum. 2013;65(Suppl 10):487.
23. Kamiya M, Sohen S, Kikuchi H. Assessment of etanercept withdrawal in rheumatoid arthritis patients in remission. Ann Rheum Dis. 2011;70(Suppl 3):414.
24. Urata Y, Nakamura Y, Motomura S. Discontinuation of etanercept in rheumatoid arthritis patients in clinical remission: two-year outcome. Ann Rheum Dis. 2012;71(Suppl 3):525.
25. Tanaka Y, Takeuchi T, Mimori T, Miyasaka N, Koike T; RRR study investigators. The possibility and predictive factors of maintaining low disease activity and joint structure after discontinuation of infliximab in RA patients: results from 3-year experience of RRR study. Ann Rheum Dis. 2013;72(Suppl 3):A443.
26. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine. 2009;76(4):350–355.
27. Pham T, Morel J, Alfaiate T, et al. Predictive factors of relapse or persistent stable remission for rheumatoid arthritis (RA) patients in remission in a TNF blocker-spacing strategy trial (STRASS trial). Arthritis Rheum. 2013;65(Suppl 10):S1021.
28. van der Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis. 2011;70(8):1389–1394.
29. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.
30. Welsing PM, Landewé RB, van Riel PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum. 2004;50(7):2082–2093.
31. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. [What is an efficient health technology in Spain?]. Gac Sanit. 2002;16(4):334–343. Spanish [with English abstract].